PainReform Ltd. (NASDAQ:PRFX) Shares Shorted: Short Interest Down 59.7% in September
by Mitch Edgeman · The Markets DailyPainReform Ltd. (NASDAQ:PRFX – Get Free Report) was the recipient of a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 27,647 shares, a decline of 59.7% from the September 15th total of 68,535 shares. Based on an average trading volume of 639,272 shares, the short-interest ratio is presently 0.0 days. Approximately 4.9% of the shares of the company are sold short.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of PainReform to a “sell” rating in a research note on Saturday, August 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of PainReform in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock has an average rating of “Sell”.
View Our Latest Analysis on PRFX
PainReform Price Performance
Shares of PRFX stock traded up $0.03 during trading hours on Thursday, hitting $0.85. The stock had a trading volume of 36,405 shares, compared to its average volume of 1,205,614. The firm has a market capitalization of $737,781.00, a PE ratio of -0.00 and a beta of 1.08. PainReform has a twelve month low of $0.81 and a twelve month high of $7.95. The stock’s 50 day moving average is $0.96 and its 200 day moving average is $1.45.
PainReform (NASDAQ:PRFX – Get Free Report) last announced its earnings results on Thursday, September 3rd. The company reported ($1.13) earnings per share (EPS) for the quarter. The firm had revenue of $0.01 million for the quarter.
About PainReform
PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on developing treatments for acute post-operative pain. The company’s goal is to provide longer-lasting pain relief at the surgical site while potentially reducing reliance on opioid medications after surgery.
PainReform’s lead product candidate, PRF-110, is an investigational extended-release formulation of the local anesthetic ropivacaine. The product is designed to be administered directly into a surgical site and provide pain relief for up to approximately 72 hours following a procedure.